Press releases
- Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
- Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
- Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
- Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
- Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
More ▼
Key statistics
On Monday, Mirum Pharmaceuticals Inc (MIRM*:MEX) closed at 629.79, 0.00% below its 52-week high of 629.79, set on Jun 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 629.79 |
---|---|
High | 629.79 |
Low | 629.79 |
Bid | -- |
Offer | -- |
Previous close | 716.77 |
Average volume | 410.00 |
---|---|
Shares outstanding | 47.13m |
Free float | 45.96m |
P/E (TTM) | -- |
Market cap | 2.04bn USD |
EPS (TTM) | -3.82 USD |
Data delayed at least 20 minutes, as of Jun 24 2024 12:30 BST.
More ▼